Navigation Links
Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product
Date:6/30/2008

materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process in various countries for the approval of the Company's products and the successful commercialization of the products throughout the world if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm Reports Results for First Quarter Fiscal 2008
2. Labopharm announces details for first quarter results conference call and annual meeting
3. Labopharm Appoints Dr. Claire Brulle as Senior Vice-President and Chief Medical Officer
4. Labopharm Appeals FDAs Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy
5. Labopharm Initiates Phase III Clinical Trial for Twice-Daily Formulation of Tramadol-Acetaminophen
6. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
7. Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
8. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
9. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
10. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
11. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Ft. Lauderdale, FL (PRWEB) July 23, 2014 ... and the largest online retailer of nutritional supplements, has ... Supplement Awards. BPI SPORTS , the fastest growing ... the following categories: , Brand of the Year, Best ... of the Year, Protein Powder of the year - ...
(Date:7/23/2014)... syndrome ( FXS ) is a genetic disorder that ... the autistic spectrum, as well as cognitive deficits. It ... and the most common cause of autism. , Now ... published a study that sheds light on ... today (July 23) in the Journal of Neuroscience ...
(Date:7/23/2014)... disorders of obesity and dementia reside in the brain, ... Behavioral Neuroscience. In the paper, researchers make the case ... the brain responsible for memory and learning. Furthermore, treatments ... in reducing certain dementias., "In the struggle to treat ... This is a new way for providers who treat ...
(Date:7/23/2014)... The voice on the recording was low and calm ... he was infected with the human immunodeficiency virus (HIV) that causes ... thing you know I was on the floor flat on my ... hopeful when the recording ended less than 10 minutes later. “Don’t ... because it is just God setting you up for something ...
(Date:7/23/2014)... PA (PRWEB) July 23, 2014 Four ... have been lauded in the latest ranking of the ... Report . Released online today and slated for ... Guide recognizes Allegheny General Hospital (AGH), Forbes Hospital, Saint ... medical centers across multiple clinical specialties. , ...
Breaking Medicine News(10 mins):Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 2Health News:Vote Now; BPI SPORTS is Nominated for Eight 2014 Bodybuilding.com Supplement Awards 3Health News:Study links enzyme to autistic behaviors 2Health News:Study links enzyme to autistic behaviors 3Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3
... antidepressant Lexapro permitted by Food and Drug Administration, U.S.// ... FDA to sell escitalopram, a generic immitator of the oral ... drug are retained by the Forest Labs till March 2012 ... This copyright is illogical as per Teva. ,Lundbeck, ...
... that volunteers distributing condoms in the province would no longer ... rates of teenage pregnancies//. The trust said that only authorized ... protection measure. ,"My concern is that child ... commented Dr Dean Marshall, deputy chairman of the BMA's Scottish ...
... statement has said that drug maker Cipla Ltd. has ... nevirapine// that is to be marketed in a tablet ... similar approval for ondansetron in the injection form. ... following chemotherapy or radiation therapy for cancer. The drug ...
... increased blood pressure. But according to a recent study ... in giving them an uninterrupted sleep at the same ... results were presented at the American Thoracic Society International ... person's physical health, and this study shows once again ...
... presented at the American Thoracic Society International Conference, it was ... in lower lung function. The study of 2,112 adolescents ages ... of vitamin D, the recommended amount for this age group. ... low dietary intake of vitamin D (157 IU or less ...
... it was found that amino acid, l-cysteine can prevent ... of the cancers occur// in the mouth, pharynx and ... drinking. This results in a strong exposure of the ... research group of Professor Mikko Salaspuro, University of Helsinki ...
Cached Medicine News:Health News:Sleep Apnea Patients Benefit from Breathing Mask 2Health News:Decreased Vitamin D Intake among Teens Results in Decreased Lung Function 2Health News:Finnish research: Cysteine Chewing Gum as a cure for cancers of the mouth 2
(Date:7/23/2014)... ROCHESTER, N.Y. , July 23, 2014 ... VSCP ), a leading provider of clinical trial ... , 48, has been named president and chief executive ... of Directors in August 2013 and has held the ... October 25, 2013. Dr. Charles E. ...
(Date:7/23/2014)... 23, 2014 Research and Markets ... in Consumer Healthcare by Application, Sensor Type & by ... 2020" report to their offering. ... an increasing momentum for consumer healthcare monitoring and sensing ... consumer healthcare will lessen the healthcare cost of the ...
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, ... in translational preclinical research, today unveiled their new logo ... the transformation of Surpass, corporate culture to one where ... customers. This press release comes on the heels of ... added to the Silicon Valley Team:  David Craig, a ...
Breaking Medicine Technology:Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 2Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 3Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc. 4Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 2Sensor Market in Consumer Healthcare (Patient Monitoring, Therapeutic, Handheld and Homecare, & Fitness and wellness) - Analysis & Forecast to to 2013 - 2020 3SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Sept. 30, 2011 Haemonetics Corporation (NYSE: ... quarter of its 2012 fiscal year on October 31, ... hold a webcast to discuss and answer questions about ... 31, 2011. Webcast Link: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=72118&eventID=4204617 ...
... Sept. 29, 2011 Boston Scientific Corporation (NYSE: ... ( NE ural C ardiac T her A ... a prospective, randomized, international clinical feasibility study designed to assess ... heart failure patients.  The study will evaluate 96 patients with ...
Cached Medicine Technology:Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 2Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 3Boston Scientific Begins Enrollment in NECTAR-HF Clinical Trial 4
Performa uncemented stem....
Standard Erlanger hip stem....
Stability cemented stem....
Porous foundation 470 series....
Medicine Products: